Afamelanotide
Back to searchMolecule Structure
Scientific Name
Afamelanotide
Description of the Drug
Afamelanotide is an injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB04931
http://www.drugbank.ca/drugs/DB04931
Brand Name(s)
Scenesse
Company Owner(s)
Clinuvel Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Melanocortin receptor 1 | SINGLE PROTEIN | AGONIST | CHEMBL3795 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL22463810 | ||||
| DrugBank | DB04931 | ||||
| PubChem: Thomson Pharma | 16681347 | 16544557 | |||
| PubChem | 91898441 | 44285019 | 16154396 | 57514683 | 16197727 |
| Nikkaji | J313.185H | ||||
| BindingDB | 50017181 | 82411 | |||
| EPA CompTox Dashboard | DTXSID40226843 | ||||
| ChemicalBook | CB4252333 | ||||
| Guide to Pharmacology | 1324 | ||||
| rxnorm | SCENESSE | AFAMELANOTIDE | AFAMELANOTIDE ACETATE | ||
| ChEBI | 136034 |
